Where is Innoviva (INVA) Headed According to Analysts?

Group 1 - Innoviva, Inc. (NASDAQ: INVA) is highlighted as a promising biotech stock with a recent price target increase from H.C. Wainwright to $45 from $40, maintaining a Buy rating [1] - Oppenheimer initiated coverage of Innoviva with an Outperform rating and a price target of $35, emphasizing the significance of its specialty therapeutics and royalty commercial results for share performance [2] - The company is engaged in the development, commercialization, and financial management of biopharmaceuticals, although some analysts suggest that certain AI stocks may offer better investment potential [3]